American Shared Hospital Services (AMS) 10-K 27 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 20, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	AMERICAN SHARED HOSPITAL SERVICES
Entity Central Index Key	744,825
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 6,858,000
Trading Symbol	AMS
Entity Common Stock, Shares Outstanding		5,468,000

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 2,871,000	$ 2,209,000
Restricted cash	250,000	50,000
Trade accounts receivable, net of allowance for doubtful accounts of $100,000 at December 31, 2016 and December 31, 2015	4,085,000	3,038,000
Other receivables	290,000	107,000
Prepaid expenses and other current assets	892,000	603,000
Total current assets	8,388,000	6,007,000
PROPERTY AND EQUIPMENT, net	51,331,000	47,123,000
INVESTMENT IN EQUITY SECURITIES	579,000	579,000
OTHER ASSETS	300,000	405,000
TOTAL ASSETS	60,598,000	54,114,000
CURRENT LIABILITIES
Accounts payable	319,000	375,000
Employee compensation and benefits	184,000	156,000
Other accrued liabilities	1,100,000	1,162,000
Current portion of long-term debt	2,205,000	2,674,000
Current portion of capital leases	4,873,000	4,331,000
Total current liabilities	8,681,000	8,698,000
LONG-TERM DEBT, less current portion	5,106,000	6,923,000
LONG-TERM CAPITAL LEASES, less current portion	14,852,000	9,190,000
DEFERRED REVENUE, less current portion	610,000	719,000
DEFERRED INCOME TAXES	4,176,000	3,404,000
COMMITMENTS AND CONTINGENCIES (See Note 12)
SHAREHOLDERS’ EQUITY
Common stock, no par value Authorized - 10,000,000 shares; Issued and outstanding shares - 5,468,000 at December 31, 2016 and 5,364,000 at December 31, 2015	10,596,000	10,376,000
Additional paid-in capital	5,949,000	5,734,000
Retained earnings	4,950,000	4,020,000
Total equity- American Shared Hospital Services	21,495,000	20,130,000
Non-controlling interests in subsidiaries	5,678,000	5,050,000
Total shareholders' equity	27,173,000	25,180,000
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 60,598,000	$ 54,114,000

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts (in dollars)	$ 100,000	$ 100,000
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,468,000	5,364,000
Common stock, shares outstanding	5,468,000	5,364,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Medical services	$ 18,700,000	$ 16,548,000	$ 15,417,000
Revenue	18,700,000	16,548,000	15,417,000
Costs of revenue:
Maintenance and supplies	874,000	1,089,000	1,691,000
Depreciation and amortization	6,262,000	6,139,000	6,171,000
Other direct operating costs	2,769,000	2,605,000	2,276,000
Costs of revenue	9,905,000	9,833,000	10,138,000
Gross margin	8,795,000	6,715,000	5,279,000
Selling and administrative expense	3,802,000	3,496,000	3,630,000
Interest expense	1,707,000	1,239,000	1,699,000
Operating income (loss)	3,286,000	1,980,000	(50,000)
(Loss) on early extinguishment of debt	(108,000)	0	0
(Loss) on write down investment in equity securities	0	(2,140,000)	0
(Loss) on sale of subsidiary	0	0	(572,000)
Gain on foreign currency transactions	0	0	161,000
Interest and other income	15,000	18,000	28,000
Income (loss) before income taxes	3,193,000	(142,000)	(433,000)
Income tax expense	943,000	434,000	129,000
Net income (loss)	2,250,000	(576,000)	(562,000)
Less: net income attributable to non-controlling interests	(1,320,000)	(946,000)	(390,000)
Net income (loss) attributable to American Shared Hospital Services	$ 930,000	$ (1,522,000)	$ (952,000)
Net income (loss) per share attributable to American Shared Hospital Services:
Income (loss) per common share- basic	$ 0.17	$ (0.28)	$ (0.19)
Income (loss) per common share- diluted	$ 0.17	$ (0.28)	$ (0.19)

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net income (loss) attributable to American Shared Hospital Services	$ 930,000	$ (1,522,000)	$ (952,000)
Other comprehensive income (loss):
Foreign currency translation adjustments	0	0	779,000
Total comprehensive income (loss)	930,000	(1,522,000)	(173,000)
Less comprehensive income attributable to the non-controlling interest	0	0	337,000
Comprehensive income (loss) attributable to American Shared Hospital Services	$ 930,000	$ (1,522,000)	$ (510,000)

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Sub-Total ASHS [Member]	Non-controlling Interest [Member]
Balances at Dec. 31, 2013	$ 24,055,000	$ 8,578,000	$ 4,990,000	$ (442,000)	$ 6,494,000	$ 19,620,000	$ 4,435,000
Balances (in shares) at Dec. 31, 2013		4,609,000
Repurchase of common stock	$ (2,000)	$ (2,000)	0	0	0	(2,000)	0
Repurchase of common stock (in shares)	(1,000)	(1,000)
Stock based compensation expense	$ 373,000	$ 0	373,000	0	0	373,000	0
Stock based compensation expense (in shares)		3,000
Private placement common stock	1,800,000	$ 1,800,000	0	0	0	1,800,000	0
Private placement common stock (in shares)		750,000
Fair value of warrants issued with promissory notes	145,000	$ 0	145,000	0	0	145,000	0
Non-controlling interest investment in subsidiaries	517,000	0	0	0	0	0	517,000
Cash distributions to non-controlling interests	(951,000)	0	0	0	0	0	(951,000)
Cumulative translation adjustment	779,000	0	0	442,000	0	442,000	337,000
Net (loss) income	(562,000)	0	0	0	(952,000)	(952,000)	390,000
Balances at Dec. 31, 2014	26,154,000	$ 10,376,000	5,508,000	0	5,542,000	21,426,000	4,728,000
Balances (in shares) at Dec. 31, 2014		5,361,000
Stock based compensation expense	226,000	$ 0	226,000	0	0	226,000	0
Stock based compensation expense (in shares)		3,000
Non-controlling interest investment in subsidiaries	46,000	$ 0	0	0	0	0	46,000
Cash distributions to non-controlling interests	(670,000)	0	0	0	0	0	(670,000)
Net (loss) income	(576,000)	0	0	0	(1,522,000)	(1,522,000)	946,000
Balances at Dec. 31, 2015	25,180,000	$ 10,376,000	5,734,000	0	4,020,000	20,130,000	5,050,000
Balances (in shares) at Dec. 31, 2015		5,364,000
Stock based compensation expense	215,000	$ 0	215,000	0	0	215,000	0
Stock based compensation expense (in shares)		4,000
Proceeds from warrants exercised	220,000	$ 220,000	0	0	0	220,000	0
Proceeds from warrants exercised ( in shares)		100,000
Non-controlling interest investment in subsidiaries	7,000	$ 0	0	0	0	0	7,000
Cash distributions to non-controlling interests	(699,000)	0	0	0	0	0	(699,000)
Net (loss) income	2,250,000	0	0	0	930,000	930,000	1,320,000
Balances at Dec. 31, 2016	$ 27,173,000	$ 10,596,000	$ 5,949,000	$ 0	$ 4,950,000	$ 21,495,000	$ 5,678,000
Balances (in shares) at Dec. 31, 2016		5,468,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
OPERATING ACTIVITIES
Net income (loss)	$ 2,250,000	$ (576,000)	$ (562,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	6,327,000	6,190,000	6,383,000
(Gain) on disposal of assets	0	0	(1,000)
Loss on early extinguishment of debt	108,000	0	0
Loss on write down investment in equity securities	0	2,140,000	0
Loss on sale of subsidiary	0	0	572,000
Deferred income tax	772,000	298,000	76,000
(Gain) on foreign currency transactions	0	0	(161,000)
Accrued interest on lease financing	414,000	0	0
Stock-based compensation expense	215,000	226,000	138,000
Other non-cash items	4,000	(31,000)	107,000
Changes in operating assets and liabilities:
Receivables	(1,230,000)	178,000	1,069,000
Prepaid expenses and other assets	(283,000)	(52,000)	11,000
Accounts payable, accrued liabilities and deferred revenue	(199,000)	175,000	(859,000)
Net cash from operating activities	8,378,000	8,548,000	6,773,000
INVESTING ACTIVITIES
Payment for purchase of property and equipment	(1,612,000)	(1,916,000)	(5,212,000)
Investment in equity securities	0	(10,000)	(8,000)
Proceeds from sale of subsidiary	0	0	768,000
Net cash used in investing activities	(1,612,000)	(1,926,000)	(4,452,000)
FINANCING ACTIVITIES
Principal payments on long-term debt	(2,968,000)	(2,058,000)	(3,263,000)
Principal payments on capital leases	(4,171,000)	(4,026,000)	(4,429,000)
Proceeds from long-term debt financing on property and equipment	570,000	1,016,000	2,625,000
Proceeds from certificate of deposit	0	9,000,000	0
Advances on line of credit	0	0	1,140,000
Payments on line of credit	0	(8,780,000)	(1,200,000)
Capital contributions from non-controlling interests	7,000	46,000	117,000
Distributions to non-controlling interests	(699,000)	(670,000)	(951,000)
Proceeds from warrants exercised	220,000	0	0
Private placements of common stock	0	0	1,800,000
Common stock repurchase	0	0	(2,000)
Proceeds from capital lease financing for reimbursement of payments for acquisition of equipment	1,137,000	0	0
Reclassification of restricted cash	(200,000)	0	0
Proceeds from promissory notes	0	0	1,000,000
Net cash used in financing activities	(6,104,000)	(5,472,000)	(3,163,000)
Net change in cash and cash equivalents	662,000	1,150,000	(842,000)
Effect of changes in foreign exchange rates on cash	0	0	(8,000)
CASH AND CASH EQUIVALENTS, beginning of year	2,209,000	1,059,000	1,909,000
CASH AND CASH EQUIVALENTS, end of year	2,871,000	2,209,000	1,059,000
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	2,150,000	1,670,000	2,070,000
Cash paid for income taxes	266,000	25,000	41,000
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Acquisition of equipment with capital lease financing	8,878,000	1,343,000	3,709,000
Warrants issued with promissory notes	0	0	145,000
Nonmonetary equipment trade-in	0	0	700,000
Equipment relieved in sale of subsidiary	0	0	(4,921,000)
Other assets relieved in sale of subsidiary	0	0	(826,000)
Debt relieved in sale of subsidiary	0	0	5,181,000
Other liabilities relieved in sale of subsidiary	0	0	14,000
Net equity relieved in sale of subsidiary	0	0	1,351,000
OCI released to net income in sale of subsidiary	0	0	(779,000)
Investment released to net income in sale of subsidiary	$ 0	$ 0	$ (1,360,000)

BUSINESS AND BASIS OF PRESENTAT

BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Business and Basis of Presentation Business – The Company (through ASRS) and Elekta AB, the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GK Financing, LLC. During 2016 GKF provided Gamma Knife units to seventeen medical centers in the United States in the states of Arkansas, California, Connecticut, Florida, Illinois, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, Tennessee, Oklahoma, Ohio, Oregon and Texas. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy (“PBRT”) and related equipment, to a new customer in the United States, which treated its first patient during the second quarter of 2016. The Company also directly provides radiation therapy and related equipment, including Intensity Modulated Radiation Therapy (“IMRT”), Image Guided Radiation Therapy (“IGRT”) and a CT Simulator to the radiation therapy department at an existing Gamma Knife site in Massachusetts. The Company formed the subsidiaries GKPeru and GKUK for the purposes of expanding its business internationally into Peru and the United Kingdom; Orlando and LBE to provide proton beam therapy services in Orlando, Florida and Long Beach, California ; and AGKE and JGKE to provide Gamma Knife services in Albuquerque, New Mexico and Jacksonville, Florida. AGKE began operation in the second quarter of 2011 and JGKE began operation in the fourth quarter of 2011. Orlando treated its first patient in April 2016. GKPeru is expected to begin operation in the third quarter of 2017. GKUK is inactive and LBE is not expected to generate revenue within the next two years. The Company continues to develop its design and business model for “The Operating Room for the 21st Century” SM (“OR21” SM), through its 50 50 MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses and other healthcare workers. This subsidiary is not operational at this time. All significant intercompany accounts and transactions have been eliminated in consolidation.

ACCOUNTING POLICIES

ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Accounting Policies – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include estimated useful lives of fixed assets and its salvage values, revenues and costs of sales for turn-key and revenue sharing arrangements, and the carrying value of its Mevion investment. Actual results could differ from those estimates. – The Company expenses advertising costs as incurred. Advertising costs were $ 279,000 115,000 155,000 – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows. Restricted cash – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. Until January 2015, most of the Company’s cash was invested in a certificate of deposit. The Company has not experienced any losses and believes it is not exposed to any significant credit risk on cash, cash equivalents and securities. The Company monitors the financial condition of the financial institutions it uses on a regular basis. All of the Company’s revenue was provided by eighteen, seventeen, and twenty customers in 2016, 2015, and, 2014, and these customers constitute accounts receivable at December 31, 2016 and 2015, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area. – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for probable losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are recorded as revenue when received. - The Company reports its non-controlling interests as a separate component of shareholders’ equity. The Company also presents the consolidated net income and the portion of the consolidated net income and other comprehensive income allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations and comprehensive income (loss). – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife, IGRT, and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 10 The Company adopted a new accounting policy for the depreciation of PBRT property and equipment. Depreciation is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 The Company capitalizes interest incurred on property and equipment that is under construction, for which deposits or progress payments have been made. When a rate is not readily available, imputed interest is calculated using the Company’s incremental borrowing rate. The interest capitalized for property and equipment is the portion of interest cost incurred during the acquisition periods that could have been avoided if expenditures for the equipment had not been made. The Company capitalized interest of $ 443,000 431,000 371,000 The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2016, the Company held equipment under operating lease contracts with customers with an original cost of $ 96,270,000 53,306,000 83,267,000 47,198,000 In July 2016, an existing customer provided notice of their intent to exercise the option to purchase the Gamma Knife unit at their hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease will terminate April 2017 and the unit will be depreciated to the purchase price at the time of the sale. Based on the guidance provided in Accounting Standards Codification (“ASC”) 360 Property, Plant and Equipment As of December 31, 2016 the Company had common stock representing an approximate 0.46 579,000 – The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. Level 1 Level 2 Level 3 Total Carrying Value December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Certificate of deposit - - - - Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Advances on line of credit - - - - - Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311 December 31, 2015 Assets: Cash, cash equivalents, restricted cash $ 2,259 $ - $ - $ 2,259 $ 2,259 Investment in equity securities - - 579 579 579 Total $ 2,259 $ - $ 579 $ 2,838 $ 2,838 Liabilities Debt obligations $ - $ - $ 9,744 $ 9,744 $ 9,597 Total $ - $ - $ 9,744 $ 9,744 $ 9,597 - Revenue is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. As of December 31, 2016, there are no guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s contracted rate. Revenue is recognized at the time the procedures are performed, based on each hospital’s contracted rate. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the Gamma Knife. The Company also records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The gross amount the Company expects to receive from the hospital, in the amount of its reimbursement from third party payors, is recorded as revenue and estimated based on historical experience and hospital contracts with third party payors. Revenue estimates are reviewed periodically and adjusted as necessary. The operating costs of the Gamma Knife and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. Revenue recognition is consistent with guidelines provided under the applicable accounting standards for revenue recognition. – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 for additional information on the Company’s stock-based compensation programs. The Company's costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites). Costs of revenues are recognized as incurred. – The Company markets its services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development and its Chief Operating Officer. The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services. The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services. – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. See Note 8 for further discussion on income taxes. – Comprehensive income (loss) encompasses all changes in shareholders’ equity other than those arising from transactions with stockholders, and consists of net loss and foreign currency translation adjustments. – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters Gains and losses from foreign currency transactions and remeasurement are listed in the Company’s consolidated statements of operations. The net foreign currency loss was $ 0 161,000 Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries of Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity 2013-05”), the Company no longer holds a financial interest in EWRS Turkey. As such, the cumulative translation adjustments previously recognized under accumulated other comprehensive (loss) were released into net income as a component of the loss for the sale of EWRS Turkey in the statement of operations. The total cumulative translation adjustment of $ 779,000 – Based on guidance provided in accordance with ASU No. 2014-08 Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity considered the sale of a significant component, but does not represent a major shift in the business, and therefore is not a discontinued operation. Effective May 31, 2014 (with closing occurring June 10, 2014) the Company sold EWRS Turkey for EUR 4.2 6.0 768,000 572,000 – Based on the guidance provided in ASC 410 Asset Retirement Obligations – Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options or warrants. 2016 2015 2014 Numerator for basic and diluted earnings (loss) per share $ 930,000 $ (1,522,000) $ (952,000) Denominator: Denominator for basic and diluted earnings (loss) per 5,570,000 5,519,000 5,028,000 Effect of dilutive securities Employee stock options 13,000 - - Denominator for diluted (loss) earnings per 5,583,000 5,519,000 5,028,000 Earnings (loss) per common share- basic $ 0.17 $ (0.28) $ (0.19) Earnings (loss) per common share- diluted $ 0.17 $ (0.28) $ (0.19) In 2016, options outstanding to purchase 581,000 2.43 3.15 In 2015, options outstanding to purchase 614,000 2.05 3.15 200,000 2.20 In 2014, options outstanding to purchase 633,000 2.43 6.16 200,000 2.20 - Based on the guidance provided in accordance with ASC 280 Segment Reporting The Company did not have any international operations as of December 31, 2016, but the Company’s unit in Peru is expected to begin operations in 2017 and is reflected in the property and equipment table below for 2016. 2016 2015 2014 Medical services revenues Domestic 100 % 100 % 97 % Foreign 0 % 0 % 3 % Total 100 % 100 % 100 % 2016 2015 2014 Property and equipment, net Domestic 93 % 93 % 94 % Foreign 7 % 7 % 6 % Total 100 % 100 % 100 % Nonmonetary Transactions 700,000 Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. No such impairment has been noted as of December 31, 2016 and 2015. – In May 2014, the Financial Accounting Standards Board “(FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606, In August 2014, FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items In February 2015, the FASB issued ASU No. 2015-02, Consolidation In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company adopted ASU 2015-03 on January 1, 2016, on a retrospective basis. Debt issuance costs that were previously recorded as other assets on the Company’s condensed consolidated Balance Sheets were reclassified as an offset to the respective debt instrument for which they were derived. As of December 31, 2016 and December 31, 2015, $ 67,000 72,000 In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02 Leases In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows (Topic 230) – Restricted Cash

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 3 – Property and Equipment DECEMBER 31, 2016 2015 Medical equipment and facilities $ 96,270,000 $ 83,267,000 Office equipment 537,000 721,000 Deposits and construction in progress 6,073,000 5,796,000 Deposits towards purchase of proton beam systems 2,000,000 5,000,000 104,880,000 94,784,000 Accumulated depreciation (53,549,000) (47,661,000) Net property and equipment $ 51,331,000 $ 47,123,000 The Company has equipment that is secured under capitalized leases, which is included in Medical equipment and facilities, with a total cost of $ 43,703,000 16,642,000 31,025,000 13,417,000 1,483,000 As of December 31, 2016, the Company has $ 6,073,000 3,500,000 As of December 31, 2016, the Company has $ 2,000,000 400,000

INVESTMENT IN EQUITY SECURITIES

INVESTMENT IN EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2016
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	Note 4 – Investment in Equity Securities As of December 31, 2016 and December 31, 2015 the Company had a $ 579,000 0.46 Based on guidance provided in ASC 320 Investments–Debt and Equity Securities Topic 5M Other Than Temporary Impairment (“OTTI”) of Certain Investments in Equity Securities 600,000 2,114,000 $ 2,114,000 During the period ended December 31, 2015, the Company engaged a third party expert to review and corroborate its assessment of the fair value of the Mevion investment. The third party utilized the market approach and an option waterfall model calibrated to Mevion’s last round of funding. Each equity class was examined and priced according to its liquidation preferences. Based on the third party analysis, an additional impairment loss of $ 26,000 579,000 2,140,000 The Company reviewed this investment at December 31, 2016 in light of both current market conditions and the ongoing needs of Mevion to raise cash to continue its development of the first compact, single room PBRT system. Based on its analysis, the Company determined no additional impairment needs to be recognized as of December 31, 2016. The Company’s first MEVION S250 PBRT unit was contracted with Orlando Health, Inc. under a ten (10) year, revenue sharing arrangement. The Marjorie and Leonard Williams Center for Proton Therapy at Orlando Health treated its first patient on April 6, 2016.

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	Note 5 – Long-Term Debt Long-term debt consists primarily of six notes with financing companies collateralized by the Gamma Knife equipment having an aggregate net book value of $ 14,684,000 These notes are payable in 12 to 84 fully amortizing monthly installments, mature between June 2018 and November 2021 3.95 7.48 Year ending December 31, Principal Interest 2017 $ 2,205,000 $ 378,000 2018 2,146,000 247,000 2019 1,536,000 138,000 2020 963,000 61,000 2021 461,000 14,000 Thereafter - - $ 7,311,000 $ 838,000

OBLIGATIONS UNDER CAPITAL LEASE

OBLIGATIONS UNDER CAPITAL LEASES	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt and Capital Leases Disclosures [Text Block]	Note 6 – Obligations Under Capital Leases The Company has twelve capital lease obligations with four financing companies, collateralized by Gamma Knife and PBRT equipment having an aggregate net book value of $ 27,061,000 4.73 13.00 17,608,000 Net Present Value of Minimum Lease Payments Year ending December 31, 2017 $ 6,725,000 2018 5,439,000 2019 4,184,000 2020 2,869,000 2021 5,066,000 Thereafter 218,000 Total capital lease payments 24,501,000 Less imputed interest 4,776,000 19,725,000 Less current portion 4,873,000 $ 14,852,000

LINE OF CREDIT

LINE OF CREDIT	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 – Line of Credit As of December 31, 2014 the Company had a $ 9,000,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 8 – Income Taxes As of December 31, 2016, 2015 and 2014 the Company recorded income tax provision expense of $ 943,000 434,000 129,000 0 YEARS ENDED DECEMBER 31, 2016 2015 2014 Current: Federal $ 24,000 $ 35,000 $ - State 146,000 103,000 54,000 Foreign - - - Total current 170,000 138,000 54,000 Deferred: Federal 680,000 353,000 (131,000) State 93,000 (57,000) 40,000 Foreign - - 166,000 Total deferred 773,000 296,000 75,000 $ 943,000 $ 434,000 $ 129,000 DECEMBER 31, 2016 2015 Deferred tax liabilities: Property and equipment $ (7,595,000) $ (6,831,000) Total deferred tax liabilities (7,595,000) (6,831,000) Deferred tax assets: Net operating loss carryforwards 2,783,000 2,859,000 Accruals and allowances 193,000 172,000 Tax credits 380,000 356,000 Other – net 200,000 163,000 Capital loss carryover 1,228,000 1,217,000 Total deferred tax assets 4,784,000 4,767,000 Valuation allowance (1,365,000) (1,340,000) Deferred tax assets net of valuation allowance 3,419,000 3,427,000 Net deferred tax liabilities $ (4,176,000) $ (3,404,000) DECEMBER 31, 2016 2015 Deferred income taxes (non-current) $ (4,176,000) $ (3,404,000) $ (4,176,000) $ (3,404,000) 34 YEARS ENDED DECEMBER 31, 2016 2015 2014 Computed expected federal income tax $ 637,000 $ (360,000) $ (280,000) State income taxes, net of federal benefit 169,000 (55,000) 66,000 Non-deductible expenses 42,000 40,000 21,000 Change in valuation allowance 25,000 792,000 416,000 Other 70,000 17,000 (94,000) $ 943,000 $ 434,000 $ 129,000 At December 31, 2016, the Company has a net operating loss carryforward for federal income tax return purposes of approximately $ 7,589,000 1,041,000 541,000 Utilization of the domestic NOL and tax credit forwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by the Internal Revenue Code Section 382, as well as similar state provisions. In general, an “ownership change,” as defined by the code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 At December 31, 2016, the Company has a capital loss carryforward for federal income tax return purposes of approximately $3,316,000 which starts to expire in 2018. The Company has capital loss carryforwards for state income tax purposes of approximately $150,000 which starts to expire in 2018. Due to the uncertainty that the Company will generate capital gains in future years to utilize its capital loss carryforward, a valuation allowance has been placed against the deferred tax asset. Due to uncertainty surrounding the realization of impairment losses, capital losses and foreign operating losses in future years, the Company has placed a valuation allowance against a portion of its net domestic and foreign deferred tax assets. The net valuation allowance increased by $25,000, $792,000, and $416,000 for the tax years ended December 31, 2016, 2015, and 2014, respectively. The tax return years 2012 through 2016 remain open to examination by the major domestic taxing jurisdictions to which the Company is subject. Net operating losses generated on a tax return basis by the Company for calendar years 1999 through 2004, 2009, 2010, 2012, 2014, 2015, and 2016 remain open to examination by the major domestic taxing jurisdictions. The Company has adopted accounting standards which prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Additionally, these accounting standards specify that tax positions for which the timing of the ultimate resolution is uncertain should be recognized as long-term liabilities. The Company has made no reclassifications between current taxes payable and long term taxes payable under this guidance. Also, the Company had no amounts of unrecognized tax benefits that, if recognized, would affect its effective income tax rate for the years ended December 31, 2016, 2015 and 2014. The Company’s policy for deducting interest and penalties is to treat interest as interest expense and penalties as taxes. As of December 31, 2016, the Company had no amount accrued for the payment of interest and penalties related to unrecognized tax benefits.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Shareholders’ Equity Incentive Compensation Plan In June 2010 shareholders approved an amendment and restatement of the Company’s stock incentive plan, renaming it the Incentive Compensation Plan (the “Plan”), and among other things, increasing the number of shares of the Company’s common stock reserved for issuance under the Plan to 1,630,000 658,000 The Plan provides for nonqualified stock options, qualified (or incentive) stock options and stock grants. The Plan has a provision to reduce the number of shares reserved for award and issuance under the Plan by a ratio of 1.59 The Plan also provides for an Incentive Bonus Program with incentive bonus opportunities through performance unit awards and special cash incentive programs tied to the attainment of pre-established performance milestones. Provisions of the Plan include an automatic annual grant to each non-employee director of options to purchase up to 2,000 500 5 Under the Plan, a total of 219,000 30,000 179,000 10,000 215,000 4,000 37,000 1.94 70,000 8,000 3,000 4,000 4,000 3,000 3,000 8,000 7,000 6,000 Weighted Weighted Average Average Remaining Aggregate Number Exercise Contractual Intrinsic Options of Options Price Term (Years) Value Balance at December 31, 2015 614,000 $ 2.86 5.10 Granted 20,000 $ 2.19 6.44 Exercised - $ - - Forfeited (9,000) $ 2.50 - Balance at December 31, 2016 625,000 $ 2.85 4.25 $ 315,000 Exercisable at December 31, 2016 85,000 $ 2.76 3.98 $ 50,000 The weighted average grant-date fair value of the options granted during the years 2016, 2015 and 2014 was $ 0.97 1.15 1.23 139,000 138,000 51,000 There was no cash received from options exercised under any share-based payment arrangements for the years ended December 31, 2016, 2015 and 2014, and as a result, there was no actual tax benefit realized for tax deductions from option exercises in any of those years. Weighted Average Number Grant-Date Nonvested Options of Options Fair Value Nonvested at December 31, 2015 532,000 $ 1.18 Granted 20,000 $ 0.97 Vested (12,000) $ 1.22 Forfeited - $ - Nonvested at December 31, 2016 540,000 $ 1.17 At December 31, 2016, there was approximately $ 378,000 The Company’s stock-based awards to employees are calculated using the Black-Scholes options valuation model. The Black-Scholes model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes model requires the input of highly subjective assumptions including the expected stock price volatility. The Company’s stock-based awards have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the present value estimates. For these reasons, management believes that the existing models do not necessarily provide a reliable single measure of the fair value of its stock-based awards to employees. The fair value of the Company’s option grants issued during 2016, 2015 and 2014 were estimated using assumptions for expected life, volatility, dividend yield, forfeiture rate, and risk-free interest rate which are specific to each award as summarized in the following table. The estimated fair value of the Company’s options is amortized over the period during which the optionee is required to provide service in exchange for the award, usually the vesting period. 2016 2015 2014 Expected life (years) 7.0 7.0 7.0 Expected forfeiture rate 0.0 % 0.0 % 0.0 % Expected volatility 53 % 41 % 40 % Dividend yield 0 % 0 % 0 % Risk-free interest rate 2.0 % 2.0 % 2.0 % Repurchase of Common Stock, Common Stock Warrants and Stock Options In 1999 and 2001, the Board of Directors approved resolutions authorizing the Company to repurchase up to a total of 1,000,000 1,000 72,000

RETIREMENT PLAN

RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	Note 10 – Retirement Plan The Company has a defined-contribution retirement plan (the “Retirement Plan”) that allows for a matching safe harbor contribution. For 2016, the Board of Directors elected to match participant deferred salary contributions up to a maximum of 4 28,000 27,000 39,000

OPERATING LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Operating Leases of Lessor Disclosure [Text Block]	Note 11 – Operating Leases The Company leases office space and equipment under operating leases expiring at various dates through 2016 and 2020. On August 13, 2016, the Company entered into a 7 Year ending December 31, 2017 $ 260,000 2018 267,000 2019 272,000 2020 244,000 2021 252,000 Thereafter 424,000 $ 1,719,000 Payments for repair and maintenance agreements incorporated in operating lease agreements are not included in the future minimum operating lease payments shown above. Net rent expense was $ 307,000 175,000 191,000 76,000 191,000 173,000 115,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 – Commitments and Contingencies As of December 31, 2016, the Company had commitments to purchase two MEVION S250 PBRT systems for $ 25,800,000 2,000,000 The Company and Mevion have not agreed on construction and delivery timetables for the second and third PBRT units for which the Company has purchase commitments. The Company is actively seeking sites for these units but to date has not entered into agreements with any party for either placement of a PBRT unit or the related financing. In the past, the Company and Mevion have established construction and delivery timetables, and therefore progress payment dates, only after the Company has notified Mevion that there is a proposed site for the unit. As of December 31, 2016, the Company had commitments to purchase one Gamma Knife Perfexion system, one Cobalt-60 reload, and is scheduled to install one Gamma Knife Model 4C system, which the Company previously financed and owns. Total Gamma Knife commitments as of December 31, 2016 were $ 3,160,000 200,000 2017 Thereafter Total Proton Beam Units $ - $ 25,800,000 $ 25,800,000 Gamma Knife Units 3,160,000 - 3,160,000 Total Commitments $ 3,160,000 $ 25,800,000 $ 28,960,000

NOTE, WARRANT, & COMMON STOCK P

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT	12 Months Ended
	Dec. 31, 2016
Note, Warrant And Common Stock Purchase Agreement [Abstract]
Note, Warrant And Common Stock Purchase Agreement [Text Block]	Note 13 – Note, Warrant, & Common Stock Purchase Agreement The Company entered into a common stock purchase agreement (the “Purchase Agreement”) with three members of the Company’s Board of Directors, to sell, in a private offering, an aggregate of 650,000 1,600,000 In October 2014, the Company entered into a Note and Warrant Purchase Agreement (the “Note and Warrant Purchase Agreement”) with four members of the Company’s Board of Directors to issue an aggregate of $ 1,000,000 200,000 15.0 and may be exercised for a purchase price equal to $ 2.20 100,000 100,000 During the year ended December 31, 2016, the Company paid down the Notes. Based on the guidance provided in accordance with ASC 405 Extinguishment of Liabilities Debt Modifications and Extinguishments 108,000 145,000 80,000 28,000 Concurrently with the Note and Warrant Purchase Agreement, the Company entered into a common stock purchase agreement (the “Common Stock Purchase Agreement”) with one member of the Company’s Board of Directors to sell, in a private offering, 100,000 220,000 The Company received gross proceeds of $ 1,220,000 1,000,000

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 14 – Related Party Transactions The Company’s Gamma Knife and IGRT businesses in Turkey were operated through EWRS Turkey. GKF owned indirectly 70 70 30 The Company’s Gamma Knife business is operated through its 81 19 The Company entered into a Purchase Agreement in 2014 to sell 650,000 1,600,000 1,000,000 200,000 100,000 220,000 of the Company’s Board of Directors were arm’s-length transactions. See Note 13 – Note, Warrant, & Common Stock Purchase Agreement for additional information. The Company has a common stock investment in Mevion which is recorded on the balance sheet as of December 31, 2016 at its fair value of approximately $ 579,000 2,000,000

MAJOR CUSTOMERS

MAJOR CUSTOMERS	12 Months Ended
	Dec. 31, 2016
Major Customers [Abstract]
Major Customers [Text Block]	Note 15 – Major Customers The Company’s revenue was provided by eighteen customers in 2016, seventeen customers in 2015 and twenty customers in 2014. In 2016 and 2015, one customer accounted for more than 10 10 10

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 16 – Subsequent Events On January 4, 2017, the Company entered into a Performance Share Award Agreement (the “Agreements”) with three executive officers of the Company for 162,000

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates in the preparation of financial statements – In preparing the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant accounting estimates reflected in the Company’s consolidated financial statements include estimated useful lives of fixed assets and its salvage values, revenues and costs of sales for turn-key and revenue sharing arrangements, and the carrying value of its Mevion investment. Actual results could differ from those estimates.
Advertising Costs, Policy [Policy Text Block]	Advertising costs – The Company expenses advertising costs as incurred. Advertising costs were $ 279,000 115,000 155,000
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents – The Company considers all liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents. Restricted cash is not considered a cash equivalent for purposes of the consolidated statements of cash flows.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash – Restricted cash represents the minimum cash that must be maintained in GKF to fund operations, per the subsidiary’s operating agreement, and the minimum cash that must be maintained in Orlando per the subsidiary’s financing agreement.
Business Combinations And Credit Risk [Policy Text Block]	Business and credit risk – The Company maintains its cash balances, which exceed federally insured limits, in financial institutions. Until January 2015, most of the Company’s cash was invested in a certificate of deposit. The Company has not experienced any losses and believes it is not exposed to any significant credit risk on cash, cash equivalents and securities. The Company monitors the financial condition of the financial institutions it uses on a regular basis. All of the Company’s revenue was provided by eighteen, seventeen, and twenty customers in 2016, 2015, and, 2014, and these customers constitute accounts receivable at December 31, 2016 and 2015, respectively. The Company performs credit evaluations of its customers and generally does not require collateral. The Company has not experienced significant losses related to receivables from individual customers or groups of customers in any particular geographic area.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts receivable and doubtful accounts – Accounts receivable are recorded at net realizable value. An allowance for doubtful accounts is estimated based on historical collections plus an allowance for probable losses. Receivables are considered past due based on contractual terms and are charged off in the period that they are deemed uncollectible. Recoveries of receivables previously charged off are recorded as revenue when received.
Non-controlling Interests [Policy Text Block]	Non-controlling interests - The Company reports its non-controlling interests as a separate component of shareholders’ equity. The Company also presents the consolidated net income and the portion of the consolidated net income and other comprehensive income allocable to the non-controlling interests and to the shareholders of the Company separately in its consolidated statements of operations and comprehensive income (loss).
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment – Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife, IGRT, and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally 3 10 The Company adopted a new accounting policy for the depreciation of PBRT property and equipment. Depreciation is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 The Company capitalizes interest incurred on property and equipment that is under construction, for which deposits or progress payments have been made. When a rate is not readily available, imputed interest is calculated using the Company’s incremental borrowing rate. The interest capitalized for property and equipment is the portion of interest cost incurred during the acquisition periods that could have been avoided if expenditures for the equipment had not been made. The Company capitalized interest of $ 443,000 431,000 371,000 The Company leases Gamma Knife and radiation therapy equipment to its customers under arrangements typically accounted for as operating leases. At December 31, 2016, the Company held equipment under operating lease contracts with customers with an original cost of $ 96,270,000 53,306,000 83,267,000 47,198,000 In July 2016, an existing customer provided notice of their intent to exercise the option to purchase the Gamma Knife unit at their hospital at the end of the lease term for a predetermined purchase price, pursuant to the lease agreement. The lease will terminate April 2017 and the unit will be depreciated to the purchase price at the time of the sale. Based on the guidance provided in Accounting Standards Codification (“ASC”) 360 Property, Plant and Equipment
Investment, Policy [Policy Text Block]	Investment in equity securities – As of December 31, 2016 the Company had common stock representing an approximate 0.46 579,000
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments – The Company’s disclosures of the fair value of financial instruments is based on a fair value hierarchy which prioritizes the inputs to the valuation techniques used to measure fair value into three levels. Level 1 inputs are unadjusted quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for assets or liabilities, and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability. Level 1 Level 2 Level 3 Total Carrying Value December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Certificate of deposit - - - - Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Advances on line of credit - - - - - Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311 December 31, 2015 Assets: Cash, cash equivalents, restricted cash $ 2,259 $ - $ - $ 2,259 $ 2,259 Investment in equity securities - - 579 579 579 Total $ 2,259 $ - $ 579 $ 2,838 $ 2,838 Liabilities Debt obligations $ - $ - $ 9,744 $ 9,744 $ 9,597 Total $ - $ - $ 9,744 $ 9,744 $ 9,597
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition - Revenue is recognized when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. As of December 31, 2016, there are no guaranteed minimum payments. The Company’s contracts are typically for a ten year term and are classified as either fee per use or retail. Retail arrangements are further classified as either turn-key or revenue sharing. Revenue from fee per use contracts is determined by each hospital’s contracted rate. Revenue is recognized at the time the procedures are performed, based on each hospital’s contracted rate. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Under turn-key arrangements, the Company receives payment from the hospital in the amount of its reimbursement from third party payors, and the Company is responsible for paying all the operating costs of the Gamma Knife. The Company also records an estimate of net operating profit based on estimated revenues, less estimated operating costs. The gross amount the Company expects to receive from the hospital, in the amount of its reimbursement from third party payors, is recorded as revenue and estimated based on historical experience and hospital contracts with third party payors. Revenue estimates are reviewed periodically and adjusted as necessary. The operating costs of the Gamma Knife and estimated net operating profit are recorded as other direct operating costs in the consolidated statement of operations. Revenue recognition is consistent with guidelines provided under the applicable accounting standards for revenue recognition.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation – The Company measures all stock-based compensation awards at fair value and records such expense in its consolidated financial statements over the requisite service period of the related award. See Note 8 for additional information on the Company’s stock-based compensation programs.
Cost of Sales, Policy [Policy Text Block]	Costs of revenue – The Company's costs of revenue consist primarily of maintenance and supplies, depreciation and amortization, and other operating expenses (such as insurance, property taxes, sales taxes, marketing costs and operating costs from the Company’s retail sites). Costs of revenues are recognized as incurred.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Sales and Marketing – The Company markets its services through its preferred provider status with Elekta and a direct sales effort led by its Vice President of Sales and Business Development and its Chief Operating Officer. The Company’s current business is the outsourcing of stereotactic radiosurgery services and radiation therapy services. The Company typically provides the equipment, as well as planning, installation, reimbursement and marketing support services.
Income Tax, Policy [Policy Text Block]	Income taxes – The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. See Note 8 for further discussion on income taxes.
Comprehensive Income (Loss), Policy [Policy Text Block]	Comprehensive income (loss) – Comprehensive income (loss) encompasses all changes in shareholders’ equity other than those arising from transactions with stockholders, and consists of net loss and foreign currency translation adjustments.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Functional currency – Based on guidance provided in accordance with ASC 830, Foreign Currency Matters Gains and losses from foreign currency transactions and remeasurement are listed in the Company’s consolidated statements of operations. The net foreign currency loss was $ 0 161,000
Cumulative Translation Adjustment [Policy Text Block]	Cumulative translation adjustment Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries of Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity 2013-05”), the Company no longer holds a financial interest in EWRS Turkey. As such, the cumulative translation adjustments previously recognized under accumulated other comprehensive (loss) were released into net income as a component of the loss for the sale of EWRS Turkey in the statement of operations. The total cumulative translation adjustment of $ 779,000
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations – Based on guidance provided in accordance with ASU No. 2014-08 Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity considered the sale of a significant component, but does not represent a major shift in the business, and therefore is not a discontinued operation. Effective May 31, 2014 (with closing occurring June 10, 2014) the Company sold EWRS Turkey for EUR 4.2 6.0 768,000 572,000
Asset Retirement Obligations Policy [Policy Text Block]	Asset Retirement Obligations – Based on the guidance provided in ASC 410 Asset Retirement Obligations
Earnings Per Share, Policy [Policy Text Block]	Earnings per share – Basic earnings per share excludes dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the year. The fully vested restricted stock units not issued and outstanding, are also included therein. Diluted earnings per share reflect the potential dilution that could occur if common shares were issued pursuant to the exercise of options or warrants. 2016 2015 2014 Numerator for basic and diluted earnings (loss) per share $ 930,000 $ (1,522,000) $ (952,000) Denominator: Denominator for basic and diluted earnings (loss) per 5,570,000 5,519,000 5,028,000 Effect of dilutive securities Employee stock options 13,000 - - Denominator for diluted (loss) earnings per 5,583,000 5,519,000 5,028,000 Earnings (loss) per common share- basic $ 0.17 $ (0.28) $ (0.19) Earnings (loss) per common share- diluted $ 0.17 $ (0.28) $ (0.19) In 2016, options outstanding to purchase 581,000 2.43 3.15 In 2015, options outstanding to purchase 614,000 2.05 3.15 200,000 2.20 In 2014, options outstanding to purchase 633,000 2.43 6.16 200,000 2.20
Segment Reporting, Policy [Policy Text Block]	- Based on the guidance provided in accordance with ASC 280 Segment Reporting The Company did not have any international operations as of December 31, 2016, but the Company’s unit in Peru is expected to begin operations in 2017 and is reflected in the property and equipment table below for 2016. 2016 2015 2014 Medical services revenues Domestic 100 % 100 % 97 % Foreign 0 % 0 % 3 % Total 100 % 100 % 100 % 2016 2015 2014 Property and equipment, net Domestic 93 % 93 % 94 % Foreign 7 % 7 % 6 % Total 100 % 100 % 100 %
Nonmonetary transactions [Policy Text Block]	Nonmonetary transactions Nonmonetary Transactions 700,000
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long lived asset impairment – The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the consolidated statement of operations in the period in which management determines such impairment. No such impairment has been noted as of December 31, 2016 and 2015.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently issued and adopted accounting pronouncements – In May 2014, the Financial Accounting Standards Board “(FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Technical Corrections and Improvements to Topic 606, In August 2014, FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In January 2015, the FASB issued ASU No. 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items In February 2015, the FASB issued ASU No. 2015-02, Consolidation In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs The Company adopted ASU 2015-03 on January 1, 2016, on a retrospective basis. Debt issuance costs that were previously recorded as other assets on the Company’s condensed consolidated Balance Sheets were reclassified as an offset to the respective debt instrument for which they were derived. As of December 31, 2016 and December 31, 2015, $ 67,000 72,000 In January 2016, the FASB issued ASU No. 2016-01 Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU No. 2016-02 Leases In March 2016, the FASB issued ASU No. 2016-09 Compensation – Stock Compensation In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In August 2016, the FASB issued ASU No. 2016-15 Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU No. 2016-18 Statement of Cash Flows (Topic 230) – Restricted Cash

ACCOUNTING POLICIES (Tables)

ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The estimated fair value of the Company’s assets and liabilities as of December 31, 2016 and December 31, 2015 were as follows (in thousands): Level 1 Level 2 Level 3 Total Carrying Value December 31, 2016 Assets: Cash, cash equivalents, restricted cash $ 3,121 $ - $ - $ 3,121 $ 3,121 Certificate of deposit - - - - Investment in equity securities - - 579 579 579 Total $ 3,121 $ - $ 579 $ 3,700 $ 3,700 Liabilities Advances on line of credit - - - - - Debt obligations $ - $ - $ 7,354 $ 7,354 $ 7,311 Total $ - $ - $ 7,354 $ 7,354 $ 7,311 December 31, 2015 Assets: Cash, cash equivalents, restricted cash $ 2,259 $ - $ - $ 2,259 $ 2,259 Investment in equity securities - - 579 579 579 Total $ 2,259 $ - $ 579 $ 2,838 $ 2,838 Liabilities Debt obligations $ - $ - $ 9,744 $ 9,744 $ 9,597 Total $ - $ - $ 9,744 $ 9,744 $ 9,597
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table illustrates the computations of basic and diluted earnings per share for the years ended December 31, 2016, 2015, and 2014. 2016 2015 2014 Numerator for basic and diluted earnings (loss) per share $ 930,000 $ (1,522,000) $ (952,000) Denominator: Denominator for basic and diluted earnings (loss) per 5,570,000 5,519,000 5,028,000 Effect of dilutive securities Employee stock options 13,000 - - Denominator for diluted (loss) earnings per 5,583,000 5,519,000 5,028,000 Earnings (loss) per common share- basic $ 0.17 $ (0.28) $ (0.19) Earnings (loss) per common share- diluted $ 0.17 $ (0.28) $ (0.19)
Schedule of Domestic and Foreign Break out Percentages [Table Text Block]	The following table provides a break out of domestic and foreign allocations of medical services revenues and net property and equipment: 2016 2015 2014 Medical services revenues Domestic 100 % 100 % 97 % Foreign 0 % 0 % 3 % Total 100 % 100 % 100 % 2016 2015 2014 Property and equipment, net Domestic 93 % 93 % 94 % Foreign 7 % 7 % 6 % Total 100 % 100 % 100 %

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following: DECEMBER 31, 2016 2015 Medical equipment and facilities $ 96,270,000 $ 83,267,000 Office equipment 537,000 721,000 Deposits and construction in progress 6,073,000 5,796,000 Deposits towards purchase of proton beam systems 2,000,000 5,000,000 104,880,000 94,784,000 Accumulated depreciation (53,549,000) (47,661,000) Net property and equipment $ 51,331,000 $ 47,123,000

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	The following are contractual maturities of long-term debt by year at December 31, 2016: Year ending December 31, Principal Interest 2017 $ 2,205,000 $ 378,000 2018 2,146,000 247,000 2019 1,536,000 138,000 2020 963,000 61,000 2021 461,000 14,000 Thereafter - - $ 7,311,000 $ 838,000

OBLIGATIONS UNDER CAPITAL LEA28

OBLIGATIONS UNDER CAPITAL LEASES (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum lease payments, together with the present value of the net minimum lease payments under capital leases at December 31, 2016, are summarized as follows: Net Present Value of Minimum Lease Payments Year ending December 31, 2017 $ 6,725,000 2018 5,439,000 2019 4,184,000 2020 2,869,000 2021 5,066,000 Thereafter 218,000 Total capital lease payments 24,501,000 Less imputed interest 4,776,000 19,725,000 Less current portion 4,873,000 $ 14,852,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the provision for income taxes as of December 31, 2016, 2015 and 2014 consist of the following: YEARS ENDED DECEMBER 31, 2016 2015 2014 Current: Federal $ 24,000 $ 35,000 $ - State 146,000 103,000 54,000 Foreign - - - Total current 170,000 138,000 54,000 Deferred: Federal 680,000 353,000 (131,000) State 93,000 (57,000) 40,000 Foreign - - 166,000 Total deferred 773,000 296,000 75,000 $ 943,000 $ 434,000 $ 129,000
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Significant components of the Company’s deferred tax liabilities and assets as of December 31, 2016 and 2015 are as follows: DECEMBER 31, 2016 2015 Deferred tax liabilities: Property and equipment $ (7,595,000) $ (6,831,000) Total deferred tax liabilities (7,595,000) (6,831,000) Deferred tax assets: Net operating loss carryforwards 2,783,000 2,859,000 Accruals and allowances 193,000 172,000 Tax credits 380,000 356,000 Other – net 200,000 163,000 Capital loss carryover 1,228,000 1,217,000 Total deferred tax assets 4,784,000 4,767,000 Valuation allowance (1,365,000) (1,340,000) Deferred tax assets net of valuation allowance 3,419,000 3,427,000 Net deferred tax liabilities $ (4,176,000) $ (3,404,000)
Condensed Financial Statements [Table Text Block]	These amounts are presented in the financial statements as follows: DECEMBER 31, 2016 2015 Deferred income taxes (non-current) $ (4,176,000) $ (3,404,000) $ (4,176,000) $ (3,404,000)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The provision for income taxes differs from the amount computed by applying the U.S. federal statutory tax rate ( 34 YEARS ENDED DECEMBER 31, 2016 2015 2014 Computed expected federal income tax $ 637,000 $ (360,000) $ (280,000) State income taxes, net of federal benefit 169,000 (55,000) 66,000 Non-deductible expenses 42,000 40,000 21,000 Change in valuation allowance 25,000 792,000 416,000 Other 70,000 17,000 (94,000) $ 943,000 $ 434,000 $ 129,000

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Number Exercise Contractual Intrinsic Options of Options Price Term (Years) Value Balance at December 31, 2015 614,000 $ 2.86 5.10 Granted 20,000 $ 2.19 6.44 Exercised - $ - - Forfeited (9,000) $ 2.50 - Balance at December 31, 2016 625,000 $ 2.85 4.25 $ 315,000 Exercisable at December 31, 2016 85,000 $ 2.76 3.98 $ 50,000
Schedule of Nonvested Share Activity [Table Text Block]	Weighted Average Number Grant-Date Nonvested Options of Options Fair Value Nonvested at December 31, 2015 532,000 $ 1.18 Granted 20,000 $ 0.97 Vested (12,000) $ 1.22 Forfeited - $ - Nonvested at December 31, 2016 540,000 $ 1.17
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 2014 Expected life (years) 7.0 7.0 7.0 Expected forfeiture rate 0.0 % 0.0 % 0.0 % Expected volatility 53 % 41 % 40 % Dividend yield 0 % 0 % 0 % Risk-free interest rate 2.0 % 2.0 % 2.0 %

OPERATING LEASES (Tables)

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31, 2017 $ 260,000 2018 267,000 2019 272,000 2020 244,000 2021 252,000 Thereafter 424,000 $ 1,719,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Long-term Purchase Commitment [Table Text Block]	The Company estimates the following commitments for each of the equipment systems, with expected timing of payments as follows as of December 31, 2016: 2017 Thereafter Total Proton Beam Units $ - $ 25,800,000 $ 25,800,000 Gamma Knife Units 3,160,000 - 3,160,000 Total Commitments $ 3,160,000 $ 25,800,000 $ 28,960,000

BUSINESS AND BASIS OF PRESENT33

BUSINESS AND BASIS OF PRESENTATION (Details Textual)	Dec. 31, 2016
OR21 LLC [Member]
Equity Method Investment, Ownership Percentage	50.00%
Architectural Design Company [Member]
Equity Method Investment, Ownership Percentage	50.00%

ACCOUNTING POLICIES (Details)

ACCOUNTING POLICIES (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
ASSETS
Cash, cash equivalents, restricted cash, Carrying Value	$ 2,871,000	$ 2,209,000	$ 1,059,000	$ 1,909,000
Total, Carrying Value	60,598,000	54,114,000
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	3,121,000	2,259,000
Certificate of deposit, Fair Value	0
Investment in equity securities, Fair Value	579,000	579,000
Total, Fair Value	3,700,000	2,838,000
Liabilities, Fair Value
Advances on line of credit, Fair Value	0
Debt obligations, Fair Value	7,354,000	9,744,000
Total, Fair Value	7,354,000	9,744,000
Carrying Value [Member]
ASSETS
Cash, cash equivalents, restricted cash, Carrying Value	3,121,000	2,259,000
Certificate of deposit, Carrying Value	0
Investment in equity securities, Carrying Value	579,000	579,000
Total, Carrying Value	3,700,000	2,838,000
Liabilities, Carrying Value
Advances on line of credit, Carrying Value	0
Debt obligations, Carrying Value	7,311,000	9,597,000
Total, Carrying Value	7,311,000	9,597,000
Fair Value, Inputs, Level 1 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	3,121,000	2,259,000
Certificate of deposit, Fair Value	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	3,121,000	2,259,000
Liabilities, Fair Value
Advances on line of credit, Fair Value	0
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Certificate of deposit, Fair Value	0
Investment in equity securities, Fair Value	0	0
Total, Fair Value	0	0
Liabilities, Fair Value
Advances on line of credit, Fair Value	0
Debt obligations, Fair Value	0	0
Total, Fair Value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, Fair Value:
Cash, cash equivalents, restricted cash, Fair Value	0	0
Investment in equity securities, Fair Value	579,000	579,000
Total, Fair Value	579,000	579,000
Liabilities, Fair Value
Advances on line of credit, Fair Value	0
Debt obligations, Fair Value	7,354,000	9,744,000
Total, Fair Value	$ 7,354,000	$ 9,744,000

ACCOUNTING POLICIES (Details 1)

ACCOUNTING POLICIES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Line Items]
Numerator for basic and diluted earnings (loss) per share	$ 930,000	$ (1,522,000)	$ (952,000)
Denominator:
Denominator for basic and diluted earnings (loss) per share - weighted-average shares	5,570,000	5,519,000	5,028,000
Effect of dilutive securities
Employee stock options	13,000	0	0
Denominator for diluted (loss) earnings per share - adjusted weighted-average shares	5,583,000	5,519,000	5,028,000
Earnings (loss) per common share- basic (in dollars per share)	$ 0.17	$ (0.28)	$ (0.19)
Earnings (loss) per common share- diluted (in dollars per share)	$ 0.17	$ (0.28)	$ (0.19)

ACCOUNTING POLICIES (Details 2)

ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	100.00%
Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	100.00%
Domestic [Member] | Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	100.00%	100.00%	97.00%
Domestic [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	93.00%	93.00%	94.00%
Foreign [Member] | Sales Revenue, Net [Member]
Accounting Policies [Line Items]
Break out, Percentage	0.00%	0.00%	3.00%
Foreign [Member] | Property, Plant and Equipment [Member]
Accounting Policies [Line Items]
Break out, Percentage	7.00%	7.00%	6.00%

ACCOUNTING POLICIES (Details Te

ACCOUNTING POLICIES (Details Textual) $ / shares in Units, € in Millions	Jun. 10, 2014USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2014EUR (€)shares
Accounting Policies [Line Items]
Interest Costs Capitalized		$ 443,000	$ 431,000	$ 371,000
Property Subject to or Available for Operating Lease, Net, Total		96,270,000	83,267,000
Property Subject to or Available for Operating Lease, Accumulated Depreciation		$ 53,306,000	$ 47,198,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares		581,000	614,000	633,000	633,000
Gain (Loss) on Disposition of Stock in Subsidiary		$ 0	$ 0	$ (572,000)
Warrants Issued With Promissory Notes During The Period | shares			200,000	200,000	200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 2.20	$ 2.20
Proceeds from Divestiture of Interest in Consolidated Subsidiaries		0	$ 0	$ 768,000
Fair Value of Assets Acquired		0	0	700,000
Advertising Expense		279,000	115,000	155,000
Accounting Standards Update 2015-03 [Member]
Accounting Policies [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets		67,000	72,000
EWRS [Member]
Accounting Policies [Line Items]
Payments for (Proceeds from) Investments				6,000,000
Sale of EWRS Turkey [Member]
Accounting Policies [Line Items]
Foreign Currency Transaction Gain, before Tax		$ 0	0	161,000
Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)				779,000
Payments for (Proceeds from) Investments | €					€ 4.2
Gain (Loss) on Disposition of Stock in Subsidiary	$ 572,000
Proceeds from Divestiture of Interest in Consolidated Subsidiaries				$ 768,000
PBRT [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		20 years
Mevion Medical Systems Inc [Member]
Accounting Policies [Line Items]
Cost Method Investments		$ 579,000	$ 579,000
Cost Method Investment Interest Percentage		0.46%
Maximum [Member]
Accounting Policies [Line Items]
Stock Options Exercise Price | $ / shares		$ 3.15	$ 3.15	$ 6.16
Maximum [Member] | Medical and Office equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		10 years
Minimum [Member]
Accounting Policies [Line Items]
Stock Options Exercise Price | $ / shares		$ 2.43	$ 2.05	$ 2.43
Minimum [Member] | Medical and Office equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		3 years

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 104,880,000	$ 94,784,000
Accumulated depreciation	(53,549,000)	(47,661,000)
Net property and equipment	51,331,000	47,123,000
Medical Equipment and Facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	96,270,000	83,267,000
Accumulated depreciation	(16,642,000)	(13,417,000)
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	537,000	721,000
Deposits and Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	6,073,000	5,796,000
Deposits Towards Purchase of Proton Beam Systems [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,000,000	$ 5,000,000

PROPERTY AND EQUIPMENT (Detai39

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 53,549,000	$ 47,661,000
Property, Plant and Equipment, Net, Total	51,331,000	47,123,000
Construction in Progress, Gross	6,073,000
Medical Equipment and Facilities [Member]
Property, Plant and Equipment [Line Items]
Capital Leased Assets, Gross	43,703,000	31,025,000
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	16,642,000	$ 13,417,000
Radiation Oncology Physician Group [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	400,000
Three Mevion S250 Proton Beam Radiation Therapy [Member]
Property, Plant and Equipment [Line Items]
Long Term Purchase Commitment Deposits For Assets	2,000,000
Gamma Knife Units [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net, Total	1,483,000
Peru Unit [Member]
Property, Plant and Equipment [Line Items]
Construction in Progress, Gross	$ 3,500,000

INVESTMENT IN EQUITY SECURITI40

INVESTMENT IN EQUITY SECURITIES (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Cost-method Investments [Line Items]
Other than Temporary Impairment Losses, Investments		$ 0	$ 2,140,000	$ 0
Cost-method Investments, Other than Temporary Impairment			26,000
Mevion Medical Systems Inc [Member]
Schedule of Cost-method Investments [Line Items]
Investments, Fair Value Disclosure	$ 600,000	579,000	579,000
Other than Temporary Impairment Losses, Investments	$ 2,114,000		2,140,000
Cost Method Investments		$ 579,000	$ 579,000
Cost Method Investments Ownership Percentage		0.46%	0.46%

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details)	Dec. 31, 2016USD ($)
Principal
2,017	$ 2,205,000
2,018	2,146,000
2,019	1,536,000
2,020	963,000
2,021	461,000
Thereafter	0
Long-term Debt	7,311,000
Interest
2,017	378,000
2,018	247,000
2,019	138,000
2,020	61,000
2,021	14,000
Thereafter	0
Interest	$ 838,000

LONG-TERM DEBT (Details Textual

LONG-TERM DEBT (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)
Debt Instrument [Line Items]
Long-term Debt, Description	These notes are payable in 12 to 84 fully amortizing monthly installments, mature between June 2018 and November 2021
Gamma Knife Units [Member]
Debt Instrument [Line Items]
Debt Instrument, Collateral Amount	$ 14,684,000
Maximum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	7.48%
Minimum [Member]
Debt Instrument [Line Items]
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate	3.95%

OBLIGATIONS UNDER CAPITAL LEA43

OBLIGATIONS UNDER CAPITAL LEASES (Details)	Dec. 31, 2016USD ($)
Capital Lease Obligations [Line Items]
2,017	$ 6,725,000
2,018	5,439,000
2,019	4,184,000
2,020	2,869,000
2,021	5,066,000
Thereafter	218,000
Total capital lease payments	24,501,000
Less imputed interest	4,776,000
Gross Minimum Lease Payments	19,725,000
Less current portion	4,873,000
Net Minimum Lease Payments	$ 14,852,000

OBLIGATIONS UNDER CAPITAL LEA44

OBLIGATIONS UNDER CAPITAL LEASES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Capital Lease Obligations [Line Items]
Description of Lessee Leasing Arrangements, Capital Leases	payable in 41 to 84 monthly installments, and mature between June 2017 and April 2022.
Maximum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate	13.00%
Minimum [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligation Interest Rate	4.73%
Ten Obligations [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligations		$ 17,608,000
Eleven Obligations [Member]
Capital Lease Obligations [Line Items]
Capital Lease Obligations	$ 27,061,000

LINE OF CREDIT (Details Textual

LINE OF CREDIT (Details Textual)	12 Months Ended
	Dec. 31, 2014USD ($)
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Amount Outstanding	$ 9,000,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
Federal	$ 24,000	$ 35,000	$ 0
State	146,000	103,000	54,000
Foreign	0	0	0
Total current	170,000	138,000	54,000
Deferred:
Federal	680,000	353,000	(131,000)
State	93,000	(57,000)	40,000
Foreign	0	0	166,000
Total deferred	772,000	298,000	76,000
Income Tax Expense (Benefit)	$ 943,000	$ 434,000	$ 129,000

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax liabilities:
Property and equipment	$ (7,595,000)	$ (6,831,000)
Total deferred tax liabilities	(7,595,000)	(6,831,000)
Deferred tax assets:
Net operating loss carryforwards	2,783,000	2,859,000
Accruals and allowances	193,000	172,000
Tax credits	380,000	356,000
Other - net	200,000	163,000
Capital loss carryover	1,228,000	1,217,000
Total deferred tax assets	4,784,000	4,767,000
Valuation allowance	(1,365,000)	(1,340,000)
Deferred tax assets net of valuation allowance	3,419,000	3,427,000
Net deferred tax liabilities	$ (4,176,000)	$ (3,404,000)

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Deferred income taxes (non-current)	$ (4,176,000)	$ (3,404,000)
Total deferred tax liabilities	$ 4,176,000	$ 3,404,000

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Computed expected federal income tax	$ 637,000	$ (360,000)	$ (280,000)
State income taxes, net of federal benefit	169,000	(55,000)	66,000
Non-deductible expenses	42,000	40,000	21,000
Change in valuation allowance	25,000	792,000	416,000
Other	70,000	17,000	(94,000)
Income Tax Expense (Benefit)	$ 943,000	$ 434,000	$ 129,000

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	34.00%	34.00%	34.00%
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 7,589,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 1,041,000
Net Operating Loss Carry Forwards And Other Deferred Tax Assets Percentage	50.00%
Operating Loss Carry Forward Expiration Dates	expire between 2022 and 2034
Income Tax Expense (Benefit)	$ 943,000	$ 434,000	$ 129,000
Increase (Decrease) in Income Taxes	0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	25,000	$ 792,000	$ 416,000
State and Local Jurisdiction [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	150,000
Foreign Tax Authority [Member]
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	3,316,000
Domestic Tax Authority [Member]
Income Tax Disclosure [Line Items]
Operating Loss Carryforwards	$ 541,000

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning balance	614,000
Number of Options, Granted	20,000
Number of Options, Exercised	0
Number of Options, Forfeited	(9,000)
Number of Options, Ending balance	625,000	614,000
Number of Options, Exercisable at December 31, 2015	85,000
Weighted Average Exercise Price, Beginning balance	$ 2.86
Weighted Average Exercise Price, Granted	2.19
Weighted Average Exercise Price - Exercised	0
Weighted Average Exercise Price, Forfeited	2.50
Weighted Average Exercise Price, Ending balance	2.85	$ 2.86
Weighted Average Exercise Price, Exercisable at December 31, 2015	$ 2.76
Weighted Average Remaining Contractual Term, Balance (Years)	4 years 3 months	5 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term	6 years 5 months 8 days
Weighted Average Remaining Contractual Term (Years), Exercisable at December 31, 2015	3 years 11 months 23 days
Aggregate Intrinsic Value, Balance at December 31, 2015	$ 315,000
Aggregate Intrinsic Value, Exercisable at December 31, 2015	$ 50,000

SHAREHOLDERS' EQUITY (Details 1

SHAREHOLDERS' EQUITY (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Shareholders Equity [Line Items]
Nonvested, Number of Options, Outstanding	532,000
Number of Options, Granted	20,000
Nonvested, Number of Options, Vested	(12,000)
Nonvested, Number of Options, Forfeited	0
Nonvested, Number of Options, Outstanding	540,000	532,000
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$ 1.18
Weighted Average Grant-Date Fair Value, Nonvested, Granted	0.97	$ 1.15	$ 1.23
Weighted Average Grant-Date Fair Value, Nonvested, Vested	1.22
Weighted Average Grant-Date Fair Value, Nonvested, Forfeited	0
Weighted Average Grant-Date Fair Value, Nonvested, Outstanding	$ 1.17	$ 1.18

SHAREHOLDERS' EQUITY (Details 2

SHAREHOLDERS' EQUITY (Details 2)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	7 years	7 years	7 years
Expected forfeiture rate	0.00%	0.00%	0.00%
Expected volatility	53.00%	41.00%	40.00%
Dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	2.00%	2.00%	2.00%

SHAREHOLDERS' EQUITY (Details T

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2010	Dec. 31, 2001
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.97	$ 1.15	$ 1.23
Stock Repurchase Program, Number of Shares Authorized to be Repurchased					1,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	72,000
Stock Repurchased During Period, Shares			1,000
Allocated Share-based Compensation Expense	$ 139,000	$ 138,000	$ 51,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	12,000
Restricted Stock [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	215,000
Non Vested Shares [Member]
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 378,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years
Employee [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	10,000
Incentive Compensation Plan [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				1,630,000
Provision For Reduction Of Reserved Shares				1.59
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award	2,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				219,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
Share Based Compensation Arrangement By Share Based Payment Award Remaining Number Of Shares Available For Grant	658,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 8,000	$ 7,000	$ 6,000
Employee Benefits and Share-based Compensation, Total	8,000
Offsetting Tax Benefit	3,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 4,000
Weighted Average Number of Shares, Restricted Stock	4,000	3,000	3,000
Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	500
Incentive Compensation Plan [Member] | Non Employee Directors and Corporate Secretary [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	30,000
Weighted Average Number of Shares, Restricted Stock	4,000
Retainer Fees [Member]
Class of Stock [Line Items]
Employee Benefits and Share-based Compensation, Total	$ 70,000
Retainer Fees [Member] | Incentive Compensation Plan [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 1.94
Retainer Fees [Member] | Incentive Compensation Plan [Member] | Non Employee Directors [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	179,000
Retainer Fees [Member] | Incentive Compensation Plan [Member] | Non Employee Directors and Corporate Secretary [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	37,000

RETIREMENT PLAN (Details Textua

RETIREMENT PLAN (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Cost Recognized	$ 28,000	$ 27,000	$ 39,000

OPERATING LEASES (Details)

OPERATING LEASES (Details)	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
2,017	$ 260,000
2,018	267,000
2,019	272,000
2,020	244,000
2,021	252,000
Thereafter	424,000
Total Future Minimum Payments Due	$ 1,719,000

OPERATING LEASES (Details Textu

OPERATING LEASES (Details Textual) - USD ($)	Aug. 13, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense		$ 307,000	$ 175,000	$ 191,000
Operating Leases Cumulative Loss					$ 115,000
Operating Leases, Rent Expense, Net		$ 76,000	$ 191,000	$ 173,000
Lease Expiration Period	7 years

COMMITMENTS AND CONTINGENCIES58

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2016USD ($)
Long-term Purchase Commitment [Line Items]
2,017	$ 3,160,000
Thereafter	25,800,000
Total	28,960,000
Proton Beam Unit [Member]
Long-term Purchase Commitment [Line Items]
2,017	0
Thereafter	25,800,000
Total	25,800,000
Gamma Knife Units [Member]
Long-term Purchase Commitment [Line Items]
2,017	3,160,000
Thereafter	0
Total	$ 3,160,000

COMMITMENTS AND CONTINGENCIES59

COMMITMENTS AND CONTINGENCIES (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Due, Description	Accordingly, the timing of the required payments for the remaining $25,800,000 of the Companys purchase commitments remains uncertain.
Other Commitment, Due in Next Twelve Months	$ 3,160,000
Gamma Knife Perfexion System [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	3,160,000
Other Commitment, Due in Next Twelve Months	200,000
Mevion Medical Systems Inc [Member]
Commitments And Contingencies [Line Items]
Long-term Purchase Commitment, Amount	25,800,000
Long-term Purchase Commitment, Deposits for Future Purchase	$ 2,000,000

NOTE, WARRANT, & COMMON STOCK60

NOTE, WARRANT, & COMMON STOCK PURCHASE AGREEMENT (Details Textual) - USD ($)	Jun. 12, 2014	Oct. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Common Stock, Shares, Issued			5,468,000	5,364,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.20	$ 2.20
Proceeds from Issuance of Private Placement	$ 1,600,000		$ 0	$ 0	$ 1,800,000
Gain (Loss) on Extinguishment of Debt			(108,000)	$ 0	$ 0
Class of Warrant or Right, Exercised			$ 100,000
Class of Warrant or Right, Outstanding			100,000
Notes Payable [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 145,000
Gain (Loss) on Extinguishment of Debt			108,000
Debt Instrument, Unamortized Discount			80,000
Deferred Fees From Issuance Of Note			$ 28,000
Private Placement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Sale of Stock, Number of Shares Issued in Transaction			100,000
Proceeds from Issuance of Private Placement			$ 220,000
Common Stock, Value, Subscriptions			1,220,000
Stock Issued During Period, Shares, New Issues	650,000
Note and Warrant Purchase Agreement [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Debt Instrument, Face Amount		$ 1,000,000	$ 1,000,000
Common Stock, Shares, Issued		200,000	200,000
Debt Instrument, Interest Rate, Stated Percentage		15.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.20
Warrant Expiration Term		3 years
Mevion Medical Systems Inc [Member]
Note, Warrant And Common Stock Purchase Agreement [Line Items]
Cash Payments			$ 1,000,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	Jun. 12, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 31, 2014
Related Party Transaction [Line Items]
Common Stock, Shares, Issued		5,468,000	5,364,000
Proceeds from Issuance of Private Placement	$ 1,600,000	$ 0	$ 0	$ 1,800,000
Note and Warrant Purchase Agreement [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount		$ 1,000,000			$ 1,000,000
Common Stock, Shares, Issued		200,000			200,000
Private Placement [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues	650,000
Sale of Stock, Number of Shares Issued in Transaction		100,000
Proceeds from Issuance of Private Placement		$ 220,000
GKF Subsidiary [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		81.00%
Equity Method Investment, Ownership Percentage		70.00%
U.S. Subsidiary Of Elekta [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		19.00%
EWRS LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		70.00%
EMKA [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		30.00%
Mevion Medical Systems Inc [Member]
Related Party Transaction [Line Items]
Investments, Fair Value Disclosure		$ 579,000
Deposit Assets, Total		$ 2,000,000

MAJOR CUSTOMERS (Details Textua

MAJOR CUSTOMERS (Details Textual)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	100.00%	100.00%	100.00%
Customer One [Member] | Total Revenue [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%	10.00%
Customers Two [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Customers Three [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		10.00%

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual)	Jan. 04, 2017shares
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	162,000